COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #230 of 237
1/2 Late treatment study
Sarfaraz et al., medRxiv, doi:10.1101/2020.12.28.20248920 (Preprint)
Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan
Source   PDF   Share   Tweet
Retrospective 186 hospitalized patients in Pakistan showing unadjusted HCQ mortality RR 1.45, p = 0.07. Confounding by indication is likely.

Sarfaraz et al., 1/2/2021, retrospective, Pakistan, South Asia, preprint, 7 authors.
risk of death, 45.0% higher, RR 1.45, p = 0.07, treatment 40 of 94 (42.6%), control 27 of 92 (29.3%).
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit